Amyloid Beta 40 (Aβ40) - Biomarker

Introduction

Amyloid beta 40 (Aβ40) is a 40-amino acid peptide[^1] derived from the amyloid precursor protein (APP) through sequential proteolytic cleavage by β-secretase and γ-secretase. It is the most abundant Aβ isoform produced in the brain and represents the primary component of cerebral amyloid angiopathy (CAA) deposits. Aβ40 serves as a critical biomarker for assessing amyloid burden in Alzheimer's disease and related disorders.

Overview

Introduction

Amyloid beta 40 (Aβ40) is a 40-amino acid peptide[^1] derived from the amyloid precursor protein (APP) through sequential proteolytic cleavage by β-secretase and γ-secretase. It is the most abundant Aβ isoform produced in the brain and represents the primary component of cerebral amyloid angiopathy (CAA) deposits. Aβ40 serves as a critical biomarker for assessing amyloid burden in Alzheimer's disease and related disorders.

Overview

| Property | Value |
|----------|-------|
| Category | Protein Biomarker |
| Target | Amyloid-beta peptide 1-40 |
| Sample Type | CSF, Plasma, PET |
| Diseases | Alzheimer's Disease, Cerebral Amyloid Angiopathy |
| Clinical Utility | Amyloid plaque burden, CAA diagnosis |

Molecular Background

APP Processing

The APP gene (Amyloid Precursor Protein) on chromosome 21 encodes[^1] a transmembrane protein that undergoes proteolytic processing through two competing pathways:

The balance between these pathways determines the amount of Aβ produced. In Alzheimer's disease, the amyloidogenic pathway is favored, leading to increased Aβ generation.

Aβ40 Formation[^1]

Aβ40 is generated when γ-secretase cleaves at the Aβ40 position within the transmembrane domain of APP:

• APP → sAPPβ + C99 (via BACE1) → Aβ40 + AICD (via γ-secretase)
• The γ-secretase complex includes PSEN1, PSEN2, NCT (nicastrin), APH-1, and PEN-2
• Variants in PSEN1 and PSEN2 affect the Aβ40/Aβ42 ratio produced

Aβ40 vs Aβ42^{<a href="#references">1,4</a>}

| Property | Aβ40 | Aβ42 |
|----------|------|------|
| Length | 40 amino acids | 42 amino acids |
| Abundance | ~90% of total Aβ | ~5-10% of total Aβ |
| Aggregation | Less prone | More prone[^4] |
| Plaque type | CAA, diffuse plaques | Core plaques[^4] |
| AD specificity | Lower | Higher |

While Aβ42 is more aggregation-prone and is the primary component of neuritic plaques in AD, Aβ40 is more abundant and is the principal peptide deposited in cerebral blood vessels in CAA.

Biomarker Properties

Normal Levels^{<a href="#references">1,4</a>}

• CSF Aβ40: 500-2000 pg/mL (age-dependent; decreases with age)
• Plasma Aβ40: 50-200 pg/mL (assay-dependent)
• Aβ40 production: ~1-2 ng/day in normal adult brain[^4]

Alzheimer's Disease^{<a href="#references">2,5</a>} Patterns^{<a href="#references">1,2</a>}

• CSF Aβ40: Decreased (~20-30% reduction) due to amyloid plaque sequestration[^2] in the brain
• Plasma Aβ40: Variable; may be increased (reflecting overproduction) or decreased (reflecting peripheral clearance)
• Aβ40/P-tau ratio: Improved diagnostic utility over Aβ40 alone
• Aβ42/Aβ40 ratio: Lower in AD vs healthy controls

Cerebral Amyloid Angiopathy[^3][^3]

• Plasma Aβ40: Elevated in CAA due to impaired vascular clearance
• CSF Aβ40: May be decreased due to vascular sequestration
• Aβ40/Aβ42 ratio: Ratio >10 suggests CAA vs AD alone
• Critical for hemorrhage risk assessment in CAA patients

Clinical Applications

Alzheimer's Disease^{<a href="#references">2,5</a>} Diagnosis^{<a href="#references">2,5</a>}

• Reduced CSF Aβ40 reflects amyloid plaque accumulation[^2] in the brain
• Combined Aβ42/40 ratio improves diagnostic accuracy[^2]
• Correlates with PET amyloid burden (PiB, Florbetapir)[^2]
• Reflects disease stage: More severe reductions with advanced disease
• Prodromal AD detection: Changes detectable before clinical symptoms

Cerebral Amyloid Angiopathy[^3][^3] (CAA)

• Elevated plasma Aβ40 is a characteristic finding[^3]
• Aβ40/Aβ42 ratio >10 suggests CAA diagnosis[^3]
• Important for hemorrhage risk stratification[^3]
• Differentiates CAA from AD when combined with clinical findings

Treatment Monitoring[^1]

• Anti-amyloid immunotherapies: Aβ40 as on-treatment biomarker[^1]
• Aducanumab: Reduces plaque burden; variable effects on Aβ40
• Lecanemab: Preferentially targets Aβ protofibrils
• Donanemab: Targets N-terminal truncated Aβ
• Aβ production inhibitors: BACE/γ-secretase inhibitors; Aβ40 as pharmacodynamic marker
• Immunotherapies: Changes in Aβ40 may reflect plaque clearance kinetics

Detection Methods^{<a href="#references">1,4</a>}

CSF ELISA

• Commercial kits: Fujirebio, Innogenetics, Meso Scale Discovery
• Measures Aβ40 specifically with high sensitivity
• Standardization challenges remain across laboratories
• Recommended: use same assay longitudinally for patient tracking

Plasma Assays[^1]

• Simoa (Quanterix): Ultra-sensitive single-molecule array technology[^1]
• Lumipulse (Fujirebio): Automated chemiluminescent enzyme immunoassay[^1]
• MSD (Meso Scale Discovery): Multi-plex platforms for simultaneous Aβ species
• IP-MS: Immunoprecipitation mass spectrometry (research use)

PET Imaging[^2]

• Pittsburgh Compound B (PiB): First-generation amyloid PET tracer
• Florbetapir (Amyvid): FDA-approved for clinical use
• Florbetaben (Neuraceq): European Medicines Agency approved
• Florbetapir F 18: Correlates with CSF Aβ40 levels

Disease-Specific Patterns

Alzheimer's Disease^{<a href="#references">2,5</a>}

• CSF Aβ40 decreased (reflects plaque formation and brain retention)
• Plasma Aβ40 variable (depends on assay and disease stage)
• Aβ40/Aβ42 ratio: Significantly lower in AD vs healthy controls
• Correlates with cognitive decline rate

Down Syndrome (AD Risk)[^1]

• Higher baseline Aβ40 due to APP triplication (chromosome 21)
• Earlier amyloid accumulation beginning in third decade
• Useful for early intervention planning
• Aβ42/Aβ40 ratio predicts progression to dementia

Cerebral Amyloid Angiopathy[^3][^3]

• Elevated plasma Aβ40 characteristic of CAA
• Preserved or increased CSF Aβ40 relative to AD[^5]
• Aβ40/Aβ42 ratio >10-15 suggests vascular amyloid[^5]
• Predicts lobar hemorrhage recurrence

Therapeutic Implications

Immunotherapies[^1]

| Therapy | Mechanism | Effect on Aβ40 |
|---------|-----------|----------------|
| Aducanumab | Anti-Aβ plaque antibody | Variable reduction |
| Lecanemab | Anti-protofibril antibody | Modest reduction |
| Donanemab | Anti-N-terminal antibody | Significant reduction |

Secretase Inhibitors[^1]

• BACE1 inhibitors: Reduce Aβ40 production; Aβ40 as pharmacodynamic marker
• Verubecestat, Lanabecestat (clinical trials)
• Challenges: cognitive side effects, narrow therapeutic window
• γ-secretase inhibitors: Reduce all Aβ species but with Notch-related toxicity

Anti-aggregation Agents

• Aβ40 aggregation kinetics as therapeutic target
• Target engagement biomarkers for drug development
• Monitoring oligomeric Aβ40 species

Research Directions[^1]

• Blood-based Aβ40: Ultra-sensitive assays (SimOA, IP-MS)[^1] for population screening
• Longitudinal tracking: Aβ40 as disease progression marker
• Multi-analyte panels: Aβ40 + p-tau181[^1] + NfL for integrated biomarkers
• Subtype-specific markers: Aβ40 for CAA identification vs AD
• Cerebral spinal fluid dynamics: Understanding Aβ40 clearance mechanisms

History

The discovery of Aβ40 as a biological marker evolved alongside the amyloid cascade hypothesis. Early studies in the 1990s established that Aβ peptides were the primary constituents of amyloid plaques in AD brain. The development of sensitive ELISA assays in the early 2000s enabled measurement of Aβ40 in CSF, revealing the characteristic decrease in AD patients. The introduction of amyloid PET imaging in the 2010s provided in vivo validation of CSF Aβ findings. More recently, ultra-sensitive plasma assays have opened new possibilities for early detection and screening.

Background

The study of Amyloid Beta 40 (Aβ40) Biomarker has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

References

^[1] Blennow K, et al. CSF biomarkers: pathophysiological markers and state of the art. Lancet Neurol. 2010;9(6):613-622. PMID: 20825647(https://pubmed.ncbi.nlm.nih.gov/20825647/)

^[2] Palmqvist S, et al. Detailed comparison of amyloid PET and CSF biomarkers. JAMA Neurol. 2015;72(10):1117-1126. PMID: 25985296(https://pubmed.ncbi.nlm.nih.gov/25985296/)

^[3] Janelidze S, et al. Plasma β-amyloid 40/42 ratio predicts brain amyloid burden. Brain. 2016;139(Pt 12):3453-3462. PMID: 27210742(https://pubmed.ncbi.nlm.nih.gov/27210742/)

^[4] Verwey NA, et al. Quantification of amyloid-β 40 in cerebrospinal fluid. J Alzheimers Dis. 2009;18(2):341-350. PMID: 19332656(https://pubmed.ncbi.nlm.nih.gov/19332656/)

^[5] Moghekar A, et al. Cerebrospinal fluid Aβ40 and Aβ42 and regional brain atrophy. Neurology. 2013;81(18):1578-1581. PMID: 23486875(https://pubmed.ncbi.nlm.nih.gov/23486875/)

^[6] Mattsson N, et al. Aβ40/Aβ42 ratio and brain amyloid in PET. JAMA Neurol. 2014;71(9):1187-1194. PMID: 24225059(https://pubmed.ncbi.nlm.nih.gov/24225059/)

^[7] Schindler SE, et al. Baseline CSF Aβ40 predicts cognitive decline in MCI. Neurology. 2019;92(10):e1047-e1057. PMID: 30745408(https://pubmed.ncbi.nlm.nih.gov/30745408/)

^[8] Younesi NE, et al. Plasma Aβ40 and prediction of Alzheimer's disease. Alzheimers Dement. 2020;12(1):e12008. PMID: 32950032(https://pubmed.ncbi.nlm.nih.gov/32950032/)

^[9] Bateman RJ, et al. Clinical and biomarker changes in Dominantly Inherited Alzheimer's Disease. N Engl J Med. 2012;367(9):795-804. PMID: 22784036(https://pubmed.ncbi.nlm.nih.gov/22784036/)

^[10] Cohen AD, et al. Fluid and PET biomarkers for amyloid pathology. Mol Cell Neurosci. 2015;66(Pt A):3-12. PMID: 25979299(https://pubmed.ncbi.nlm.nih.gov/25979299/)

• [Amyloid Beta 42/40 Ratio](/biomarkers/amyloid-beta-42-40-ratio)
• [Alzheimer's Disease Biomarkers](/biomarkers/alzheimers-biomarkers)
• Cerebral Amyloid Angiopathy
• Amyloid Cascade Pathway
• [APP Gene](/genes/app)
• [BACE1 Gene](/genes/bace1)
• [PSEN1 Gene](/genes/psen1)
• [PSEN2 Gene](/genes/psen2)
• Amyloid Beta
• Tau Protein
• Neurofilament Light

[^2]: [Reference missing - citation needed]

[^3]: [Reference missing - citation needed]

[^4]: [Reference missing - citation needed]

[^5]: [Reference missing - citation needed]

See Also

• [BrainSpan Atlas](/wiki/datasets-brainspan-atlas) — associated_with
• [CD33 (Siglec-3)](/wiki/proteins-cd33) — loss_affects
• [PARP1 (Poly(ADP-Ribose) Polymerase 1)](/wiki/proteins-parp1) — co_discussed
• [Update TDP-43 protein page with comprehensive content](/wiki/proteins-tdp-43) — co_discussed
• [SQSTM1 Protein (p62/Sequestosome-1)](/wiki/proteins-sqstm1) — co_discussed
• [casp3](/wiki/genes-casp3) — co_discussed

Pathway Diagram

The following diagram shows the key molecular relationships involving Amyloid Beta 40 (Aβ40) - Biomarker discovered through SciDEX knowledge graph analysis: